Investigating the Effect of Brain Electrical Stimulation on Depression and Anxiety in Patients with Inflammatory Bowel Disease

Investigating the Effect of Transcranial Electric Stimulation on Depression, Anxiety and Quality of life in Patients With Inflammatory Bowel Disease

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT20260127068675N1

Enrollment

Registered

2026-05-18

Start date

2026-05-22

Completion date

Unknown

Last updated

2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: Depressive disorders. Condition 2: Anxiety Disorders. Major depressive disorder, recurrent Generalized anxiety disorder

Interventions

Intervention 1: Intervention group: In addition to receiving standard treatment for inflammatory bowel disease, patients in this group will undergo transcranial electrical stimulation using a cranial

however, the device will not deliver active electrical stimulation. Sessions will be conducted at the Psychiatry Clinic of Taleghani Hospital.

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Diagnosis of inflammatory bowel disease including ulcerative colitis or Crohn’s disease Mild to moderate inflammatory bowel disease Presence of mild to moderate anxiety or depressive symptoms based on the Hamilton questionnaire Willingness to participate in the study and signing informed consent form

Exclusion criteria

Exclusion criteria: Severe inflammatory bowel disease Presence of severe psychiatric disorders such as bipolar disorder or schizophrenia Recent use of antidepressant or anti-anxiety medications Presence of severe or unstable concomitant medical illnesses Contraindication to the use of transcranial electrical stimulation device

Design outcomes

Primary

Measure	Time frame
Depression severity. Timepoint: Measuring the severity of depression at the beginning of the study (before the start of the intervention) and one month after the start of the intervention. Method of measurement: Hamilton Depression Questionnaire.;Anxiety severity. Timepoint: Measuring the severity of anxiety at the beginning of the study (before the start of the intervention) and one month after the start of the intervention. Method of measurement: Hamilton Anxiety Questionnaire.	—

Measure

Time frame

Depression severity. Timepoint: Measuring the severity of depression at the beginning of the study (before the start of the intervention) and one month after the start of the intervention. Method of measurement: Hamilton Depression Questionnaire.;Anxiety severity. Timepoint: Measuring the severity of anxiety at the beginning of the study (before the start of the intervention) and one month after the start of the intervention. Method of measurement: Hamilton Anxiety Questionnaire.

—

Secondary

Measure	Time frame
Quality of life. Timepoint: Measuring the quality of life at the beginning of the study (before the start of the intervention) and one month after the start of the intervention. Method of measurement: Quality of Life Questionnaire for Patients with Inflammatory Bowel Disease.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactShayesteh Rezaeii

Shahid Beheshti University of Medical Sciences

shayesteh.rezaeii@gmail.com+98 21 7755 1023

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Jun 11, 2026